Radiology

Tim261026 apple cover final

Nanox Selected as One of TIME’s Best Inventions of 2026 for its Nanox.ARC X

Radiology by 0 comments

Nanox.ARC X recognized among the “world’s most groundbreaking innovations” and for its approach to making advanced medical imaging more accessible  Marks Nanox’s second appearance on TIME’s Best Inventions list, and its first inclusion on the main list PETACH TIKVA, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) — Nanox Imaging Ltd. (NASDAQ: NNOX) (“Nanox”), a leader in innovative medical imaging technology, today announced that the Nanox.ARC X has been selected as one of TIME’s Best Inventions of 2026. See the full list here: https://time.com/collection/best-inventions/2026 TIME’s annual Best Inventions list recognizes “the products, software, and services shaping our world—from breakthroughs in science and technology to innovations making the world better, smarter, and more fun.” Nanox.ARC X is an FDA-cleared digital tomosynthesis system that captures X-ray images from multiple angles at once and delivers up to 200 coronal images per scan. It produces a 3D view of the body at up to 80% less radiation than CT for equivalent body parts and uses a standard 110V power outlet in a standard X-ray room. The Nanox.ARC X builds on Nanox’s proprietary digital Nanox.SOURCE X-ray technology and advanced tomosynthesis capabilities, combining them in a fully integrated, single-unit system with a significantly reduced physical footprint compared to a CT system. Plug-and-play installation, a simplified operator workflow, and remote upgrade capability allow the system to be deployed and maintained across a range of settings, including small and medium imaging centers, outpatient clinics, and hospitals. “It is an honor to be recognized once again on TIME’s Best Inventions list,” said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. “This recognition is a meaningful acknowledgment of the innovation behind our technology and the vision that continues to guide us: making advanced medical imaging more accessible to healthcare providers and patients around the world. We believe it reflects the progress we have made in translating that vision into reality and reinforces our commitment to advancing a more accessible future for medical imaging.” Nanox.AI’s FDA-cleared AI solutions received a “Special Mentions” recognition in TIME’s Best Inventions of 2024 list. Nanox.ARC X is the latest generation of the Nanox.ARC system. Nanox has announced Nanox.ARC distribution agreements across the United States, Europe and Latin America. Nanox will showcase Nanox.ARC X at the RSNA 2026 Annual Meeting in Chicago, booth 1759. About Nanox Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes. The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery. By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision Forward-Looking Statements This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations. Contacts Media Contact:Ben ShannonICR HealthcareNanoxPR@icrinc.com Investor Contact:Mike CavanaughICR Healthcaremike.cavanaugh@icrhealthcare.com

Continue Reading →

Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026

Coronary/Structural Heart Radiology by 0 comments

Dr. Megha Prasad to deliver podium presentation featuring Conavi’s hybrid IVUS–OCT imagingAbstract presentation on saline-based hybrid IVUS–OCT imagingParticipation in two CRF Imaging Lab physician education sessions TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced its participation in Transcatheter Cardiovascular Therapeutics (TCT) 2026, taking place October 31–November 3, 2026, at the San Diego Convention Center in San Diego, California. This will be Conavi’s first TCT conference since receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for its next-generation hybrid intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging system. Conavi will showcase the cleared system alongside an expanded scientific and educational program featuring a podium case presentation, a new preclinical abstract and participation in two CRF Imaging Lab sessions. Conavi’s technology combines the depth of IVUS with the high resolution of OCT, providing simultaneous, co-registered views of coronary arteries within a single system. TCT provides an opportunity to introduce physicians to the next-generation platform and discuss the growing role of hybrid imaging in guiding percutaneous coronary intervention (PCI). “This year’s TCT marks an important step for Conavi as we showcase our next-generation system following FDA clearance, giving physicians IVUS and OCT imaging simultaneously in a single pullback,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “With a podium presentation, an abstract and participation in physician education sessions on the program, we have a broader presence at TCT this year. We look forward to introducing physicians to our cleared system and building relationships with potential clinical users as we advance our U.S. commercialization.” Podium presentation on hybrid imaging in complex PCI“Detection of Post-Stent Medial Dissection and White Thrombus Using Hybrid IVUS OCT Imaging May Help Guide Management” Presenter: Megha Prasad, MD, MS, Columbia University Irving Medical Center/NewYork-Presbyterian HospitalDate: Monday, November 2, 2026Time: 4:30–4:35 p.m. PTTCT number: 2177Session: CHIP: Complication Cascades | TCT number: 2177Location: Complex Cases Theater 4, Sails Pavilion, Upper Level Abstract presentation on saline based hybrid imaging“Saline-Based Hybrid IVUS–OCT Imaging: Feasibility of Contrast-Free Dual-Modality Intracoronary Imaging in a Porcine Model” Presenter: Megha Prasad, MD, MS, Columbia University Irving Medical Center/NewYork-Presbyterian HospitalDate: Monday, November 2, 2026Time: 12:20 p.m. PTSession: Hybrid (IVUS/OCT) and Contrast-Free Intracoronary ImagingSession time: 12:00–1:00 p.m. PTLocation: Station 6 CRF Imaging Lab education seminarsSeminar 1 — Acute coronary syndrome, calcium and hybrid imaging Date: Tuesday, November 3, 2026Time: 8:00–9:30 a.m. PTConavi hybrid imaging presentation: 9:10 a.m., led by Megha Prasad, MDModerator: Khady Fall, MDLocation: Imaging Pavilion Seminar 2 — Left main/bifurcation disease, chronic total occlusion and in-stent restenosis Date: Tuesday, November 3, 2026Time: 10:00–11:30 a.m. PTModerators: Akiko Maehara, MD, and Mitsuaki Matsumura, PhDLocation: Imaging Pavilion About TCTOrganized by the Cardiovascular Research Foundation, Transcatheter Cardiovascular Therapeutics is an international educational meeting focused on interventional cardiovascular medicine, bringing together physicians, researchers and industry to share research and advances in catheter-based therapies. About Conavi MedicalConavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/. Forward looking informationThis press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. ContactMark Quick, Chief Financial Officer | 416-483-0100Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com

Continue Reading →

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

Financial Radiology by 0 comments

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec

Continue Reading →

Riverain Technologies Expands Access to ClearRead™ Advanced Chest Imaging AI Through RapidAI’s Enterprise Platform

Coronary/Structural Heart Radiology by 0 comments

ClearRead Chest integration extends Riverain’s clinically proven cardiothoracic AI suite of solutions through a unified enterprise workflow designed to reduce fragmentation and accelerate action   MIAMISBURG, Ohio, October 6, 2026 — Riverain Technologies, a leader in cardiothoracic imaging AI, today announced that its FDA-cleared ClearRead™ Chest suite will be available […]

Continue Reading →

Inquis Medical Launches First Thrombectomy Catheter with Full 360° Directional Aspiration for Pulmonary Embolism

Peripheral/Endo Radiology by 0 comments

MENLO PARK, Calif.–(BUSINESS WIRE)– #AVENTUSThrombectomy–Inquis Medical, a medical device company pioneering advanced treatments for venous thromboembolic disease, today announced the U.S. commercial launch of the latest AVENTUS™ Catheter, designed to provide physicians with 360° sweeping directional aspiration for clot removal within the vasculature. Austin Bourgeois, MD, performed the first-in-human pulmonary embolism (PE) procedure using the new catheter at Huntsville Hospital in Huntsville, Alabama. AVENTUS is

Continue Reading →

GuideAI Health Corp. and vRad Renew Data Exclusivity Agreement to Develop AI Models for the Detection and Characterization of Multiple Vascular Diseases

Radiology by 0 comments

Company holds exclusive access to imaging data from 2,100+ U.S. hospitals through its ongoing data partnership with vRad, the largest teleradiology provider in the United StatesBOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — GuideAI Health Corp. (Cboe CA: GDAI) (FSE: ZN0) (“GuideAI” or the “Company”) is pleased to announce the renewal of its data exclusivity agreement with vRad (Virtual Radiologic), which aims to develop artificial intelligence models for the detection and characterization of multiple vascular diseases. The renewed collaboration provides GuideAI with exclusive access to imaging data from more than 2,100 hospitals across the United States, which the Company believes to be one of the largest and most diverse real-world imaging datasets of its kind. Under the renewed partnership, GuideAI retains exclusive rights to develop AI models using de-identified imaging data generated across vRad’s national network of more than 2,100 hospitals and healthcare facilities. GuideAI’s technology is currently deployed within the workflow of vRad’s approximately 500 radiologists, where it supports the identification of vascular disease at the point of care. The scale and diversity of vRad’s dataset provide GuideAI with a durable foundation on which to train and validate its algorithms. Building on its work in peripheral arterial disease, the Company intends to expand its platform to the detection and characterization of multiple vascular diseases, with the goal of surfacing disease earlier and supporting more precise, more comprehensive treatment decisions for patients nationwide. GuideAI Health CEO, Raj Shah, commented, “Renewing our exclusive data collaboration with vRad is a defining moment for GuideAI. Access to imaging data from more than 2,100 hospitals, combined with the trust of the 500 radiologists who already have access to our technology in their daily workflow, gives us an exceptional foundation to build clinically meaningful AI, furthering our aim of helping clinicians catch disease earlier and improve outcomes for patients.” About GuideAI Health Corp. GuideAI Health Corp. is a healthcare technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease. By surfacing disease earlier, GuideAI aims to improve patient outcomes while helping hospitals and radiology groups deliver more comprehensive vascular care. For more information, please visit www.guideaihealth.com. On Behalf of the Board of Directors: Raj Shah CEO Contact: Phone: (416) 309-3583Email: info@guideaihealth.com Cautionary Note Regarding Forward-Looking Statements This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking information”). Forward-looking information in this news release includes, but is not limited to, statements regarding: the continuation and anticipated benefits of the Company’s renewed data exclusivity agreement and collaboration with vRad; the Company’s continued exclusive access to, and ability to use, de-identified imaging data generated across vRad’s network; the scope, scale, diversity and anticipated value of that dataset; the continued deployment and use of GuideAI’s technology within vRad’s radiology workflow; the Company’s ability to train, develop, validate and commercialize artificial intelligence models for the detection and characterization of vascular diseases; the expansion of the Company’s platform beyond peripheral arterial disease; the potential for the Company’s technology to identify disease earlier, support more precise and comprehensive treatment decisions and improve patient outcomes; and the Company’s business plans, objectives and future activities. Forward-looking information is often, but not always, identified by words or phrases such as “anticipates”, “believes”, “expects”, “intends”, “plans”, “aims”, “goal”, “may”, “will”, “would”, “could”, “should”, “potential”, “continue” and similar expressions.  Forward-looking information is based on management’s estimates, assumptions and expectations as of the date of this news release, including assumptions regarding: the continued validity and enforceability of, and performance by the parties under, the renewed agreement; the Company’s continued ability to access and lawfully use sufficient quantities of de-identified imaging data; the quality, completeness, diversity and representativeness of the available data; the continued availability, performance and integration of the Company’s technology within vRad’s workflow; the Company’s ability to retain qualified personnel, secure required financing and other resources, protect its intellectual property and data rights, and complete development, testing and validation activities; and the receipt of any required regulatory, clinical, commercial or third-party approvals. Although the Company considers these assumptions reasonable, they may prove to be incorrect.  Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied, including risks relating to: the termination, non-renewal, amendment, breach or unenforceability of the renewed agreement; interruptions, restrictions or loss of access to imaging data or the vRad network; limitations in the quantity, quality, completeness, diversity or representativeness of available data; privacy, data protection, cybersecurity, data de-identification, consent and regulatory compliance; the accuracy, reliability, generalizability, validation and clinical utility of artificial intelligence models; development delays, technical failures, integration challenges and the inability to achieve expected performance or commercial objectives; changes in laws, regulations, standards of care or regulatory requirements applicable to artificial intelligence, medical devices, healthcare or data use; failure to obtain or maintain required approvals; intellectual property disputes and the inability to protect proprietary rights; competition and technological change; dependence on key personnel, collaborators, service providers and third parties; the availability of capital and other resources; and the possibility that the anticipated clinical, operational or commercial benefits of the collaboration and the Company’s technology will not be realized. Additional risks are described in the Company’s public disclosure documents available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Continue Reading →

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

Radiology by 0 comments

WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery™ (PEDD) portfolio. TriNav® Advance expands Tri

Continue Reading →

Philips-led projects win ITEA awards for advancing AI-enabled healthcare innovation

Radiology by 0 comments

Winners of the 2026 ITEA Awards of Excellence

Winners of the 2026 ITEA Awards of Excellence

September 16, 2026 SYMPHONY receives ITEA’s highest excellence award for connected healthcare ecosystemsAI FORSchung is recognized for innovation in AI-powered fiber-optic sensing Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that two Philips-led public-private research collaborations have received ITEA Awards of Excellence 2026 for advancing AI-enabled innovation in healthcare. SYMPHONY received the ITEA Award of Excellence for “Exceptional Excellence” for connecting healthcare data, clinical workflows and AI-supported decision tools through open, interoperable ecosystems. AI FORSchung received the ITEA Award of Excellence for Innovation for developing AI-driven methods to compress and analyze large volumes of fiber-optic sensing data. The awards were presented at the ITEA PO Days 2026 in Istanbul, Turkey. Connecting data and AI around clinical workflowsSYMPHONY developed a reusable, vendor-neutral reference architecture and demonstrated connected healthcare ecosystems across four clinical areas: prostate cancer, aortic aneurysm, atrial fibrillation and multiple sclerosis with clinical partners including Leiden University Medical Center, Amsterdam University Medical Center and Karolinska University Hospital. Philips also developed technology within SYMPHONY to automatically segment and measure vascular structures in medical images, supporting the assessment and follow-up of aortic aneurysms. The resulting functionality has received FDA clearance and CE marking and is included in AV Vascular, a part of the Philips AV Cardiovascular Suite.“Healthcare AI creates the greatest value when it can work with the information and clinical workflows that care teams already depend on,” said Sanjay Gandhi, Head of Medical Affairs & Clinical Partnerships at Philips. “SYMPHONY shows what becomes possible when healthcare providers, researchers and technology companies build around open standards and clinical pathways rather than isolated applications.” This real-world implementation was demonstrated through many close collaborations including the one between Philips and Leiden University Medical Center (LUMC), where standards-based integration was the focus. “Together with Philips, the LUMC demonstrated in SYMPHONY how vendor-neutral, standards-based integration of clinical data, imaging and applications, including the AV Vascular Segmentation solution, can support real clinical workflows,” said Jouke Dijkstra, Associate Professor, Vascular and Molecular Imaging at LUMC. The project created a reusable foundation for deploying innovative digital health solutions, also tailored towards AI algorithm integration, across institutions and disease areas.” Making growing sensing datasets more manageableFiber Optic RealShape (FORS) technology is used to support medical device navigation during image-guided procedures, generating large volumes of position data that need to be stored and processed efficiently. Within AI FORSchung, researchers developed new methods to make these data volumes easier to manage, demonstrating that FORS position data could be compressed more than 20 times while maintaining performance within the evaluated datasets.“The challenge extends well beyond healthcare,” said Ahmet Ekin, Senior Designer at Philips. “Fiber-optic sensing is also used to monitor critical infrastructure such as pipelines, bridges and tunnels, where continuous monitoring generates substantial volumes of data. By developing approaches that can be applied across healthcare, utilities and civil infrastructure, AI FORSchung demonstrated how advances in one field can help address shared data challenges in another.Both projects were conducted within ITEA, the Eureka Research, Development and Innovation Cluster on software innovation, funded by multiple national authorities including the Netherlands Enterprise Agency (RVO). Additional information about SYMPHONY can be found here: https://itea4.org/project/symphony.html; https://symphony-iteaproject.eu/Additional information about AI FORSchung can be found here: https://itea4.org/project/ai-forschung.html For further information, please contact: Joost MalthaPhilips Global External RelationsTel.: +31 6 1055816E-mail: joost.maltha@philips.com About Royal Philips  Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment

Winners of the 2026 ITEA Awards of Excellence

Continue Reading →
1 2 3 … 81